Although trading nipped shares of United Therapeutics Corp. when the news broke, few onlookers likely felt shock when the data monitoring committee (DMC) decreed earlier this month that the company keep going with its Freedom-Ev trial testing vasodilator Orenitram (treprostinil extended-release tablets).